Skip to Main Content

Paper Details

Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma.
Pediatr Blood Cancer
1
2023
Copanlisib, PI3K, PI3K class I isoforms, class I phosphoinositide 3-kinase, copanlisib, osteosarcoma, osteosarcoma tumor, tumor
Author NameAffiliation
Wendong ZhangUniversity of Texas MD Anderson Cancer Center
Peter J HoughtonGreehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio
Malcolm A SmithNational Cancer Institute
Malcolm A SmithNational Cancer Institute
Edward A KolbNemours/Alfred I. duPont Hospital for Children
Richard GorlickUniversity of Texas MD Anderson Cancer Center
Richard GorlickUniversity of Texas MD Anderson Cancer Center
  • 1 - 7

Datasets

Release 1.2